Daily Stock Analysis, IOVA, Iovance Biotherapeutics Inc, priceseries

Iovance Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
25.80
Close
25.47
High
26.59
Low
25.43
Previous Close
25.78
Daily Price Gain
-0.31
YTD High
26.59
YTD High Date
Jul 19, 2019
YTD Low
8.26
YTD Low Date
Jan 24, 2019
YTD Price Change
16.02
YTD Gain
169.52%
52 Week High
26.59
52 Week High Date
Jul 19, 2019
52 Week Low
7.26
52 Week Low Date
Dec 21, 2018
52 Week Price Change
10.57
52 Week Gain
70.94%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 23. 2017
5.00
Sep 20. 2017
7.16
19 Trading Days
43.15%
Link
LONG
Oct 27. 2017
7.30
Nov 1. 2017
7.78
3 Trading Days
6.51%
Link
LONG
Nov 20. 2017
8.30
Dec 4. 2017
8.74
9 Trading Days
5.29%
Link
LONG
Jan 9. 2018
8.55
Feb 23. 2018
16.40
31 Trading Days
91.84%
Link
LONG
May 15. 2018
15.25
May 25. 2018
16.15
8 Trading Days
5.93%
Link
LONG
Apr 1. 2019
9.78
Apr 15. 2019
11.36
10 Trading Days
16.15%
Link
Company Information
Stock Symbol
IOVA
Exchange
NasdaqGM
Company URL
http://www.lionbio.com
Company Phone
6502607120
CEO
Maria Fardis
Headquarters
California
Business Address
999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA 94070
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001425205
About

Lion Biotechnologies, Inc. operates as a biotechnology company which focuses on the development and commercialization of novel cancer immunotherapy. It products designed to harness the power of a patient's own immune system to eradicate cancer cells. The company services include adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. Lion Biotechnologies was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Description

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York.